Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120


Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.

van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P.

Haematologica. 2011 Nov;96(11):1662-9. doi: 10.3324/haematol.2010.037978. Epub 2011 Jul 26.


Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma.

Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander AR, Bokemeyer C, Kröger N.

Clin Cancer Res. 2009 Feb 15;15(4):1343-52. doi: 10.1158/1078-0432.CCR-08-0989. Epub 2009 Feb 3.


Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients.

Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, Chauffaille ML, Andriolo A, Caballero OL, Zago MA, Colleoni GW.

Cancer Immun. 2008 Feb 1;8:2.


Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.

Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B.

J Immunol. 2007 Mar 1;178(5):3307-15.


SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.

Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, Belch AR, Pilarski LM.

J Immunother. 2005 Nov-Dec;28(6):564-75.


Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM.

Haematologica. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585. Epub 2013 Aug 30.


Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.

Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C, Kröger N.

Haematologica. 2010 May;95(5):785-93. doi: 10.3324/haematol.2009.014464. Epub 2009 Dec 16.


Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy.

Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E.

J Immunother. 2011 Jul-Aug;34(6):490-9. doi: 10.1097/CJI.0b013e31821ca76f.


Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.

Bodey B.

Expert Opin Biol Ther. 2002 Aug;2(6):577-84. Review.


Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.

Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P.

Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.


Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens.

Ghafouri-Fard S, Seifi-Alan M, Shamsi R, Esfandiary A.

Iran J Cancer Prev. 2015 Oct;8(5):e3755. doi: 10.17795/ijcp-3755. Epub 2015 Oct 27. Review.


Expression of cancer-testis antigen in multiple myeloma.

He L, Ji JN, Liu SQ, Xue E, Liang Q, Ma Z.

J Huazhong Univ Sci Technolog Med Sci. 2014 Apr;34(2):181-5. doi: 10.1007/s11596-014-1255-7. Epub 2014 Apr 8.


High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells.

Wen J, Li H, Tao W, Savoldo B, Foglesong JA, King LC, Zu Y, Chang CC.

Br J Haematol. 2014 Sep;166(5):711-9. doi: 10.1111/bjh.12951. Epub 2014 May 29.


High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P; Dutch-Belgian HOVON group; German GMMG Group.

Blood. 2013 Jan 24;121(4):624-7. doi: 10.1182/blood-2012-06-438101. Epub 2012 Dec 11.


MAGE-C1/CT7 and MAGE-C2/CT10 are frequently expressed in multiple myeloma and can be explored in combined immunotherapy for this malignancy.

de Carvalho F, Alves VL, Braga WM, Xavier CV Jr, Colleoni GW.

Cancer Immunol Immunother. 2013 Jan;62(1):191-5. doi: 10.1007/s00262-012-1376-4. Epub 2012 Nov 22.


Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma.

Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, Hossfeld DK, Hegewisch-Becker S, Bokemeyer C, Leuwer R.

Cancer Biol Ther. 2006 Sep;5(9):1218-25. Epub 2006 Sep 9.


Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.

Hermansen NE, Borup R, Andersen MK, Vangsted AJ, Clausen NT, Kristensen DL, Nielsen FC, Gimsing P.

Int J Lab Hematol. 2016 Jun;38(3):298-307. doi: 10.1111/ijlh.12486. Epub 2016 Mar 29.


MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.

Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang X, Dabrowski A, Andrade VC, Wasserstrum R, Ely S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, Bhardwaj N, Old LJ, Chen-Kiang S, Cho HJ.

Clin Cancer Res. 2011 Jul 1;17(13):4309-19. doi: 10.1158/1078-0432.CCR-10-1820. Epub 2011 May 12.


Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma.

Qin Y, Lu J, Bao L, Zhu H, Li J, Li L, Lai Y, Shi H, Wang Y, Liu Y, Jiang B, Huang X.

Chin Med J (Engl). 2014;127(9):1666-71.


Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma.

Lim SH, Wang Z, Chiriva-Internati M, Xue Y.

Blood. 2001 Mar 1;97(5):1508-10.

Supplemental Content

Support Center